Bruno
Paiva
Profesional Investigador
Universidad de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Salamanca (60)
2023
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
Science Advances, Vol. 8, Núm. 3
2021
-
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
Modern Pathology, Vol. 34, Núm. 1, pp. 59-69
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
Blood Cancer Journal, Vol. 11, Núm. 2
-
Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma
Cancers, Vol. 13, Núm. 6, pp. 1-18
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia, Vol. 34, Núm. 2, pp. 589-603
2019
-
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Blood
-
EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets
Journal of Immunological Methods, Vol. 475
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267